Phase II Trial of Palbociclib (PD-0332991) in Patients With Metastatic Urothelial Cancer (UC) After Failure of First-Line Chemotherapy

Trial Profile

Phase II Trial of Palbociclib (PD-0332991) in Patients With Metastatic Urothelial Cancer (UC) After Failure of First-Line Chemotherapy

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs Palbociclib (Primary)
  • Indications Urogenital cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Oct 2017 Status changed from recruiting to discontinued because the data from the first 12 participants made it apparent that the study was not going to meet the primary endpoint
    • 10 Mar 2017 Planned End Date changed from 1 Jan 2025 to 1 Jul 2021.
    • 10 Mar 2017 Planned primary completion date changed from 1 Jan 2020 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top